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tethinking Loading
ose Clopidogrel in
ight of Increased Bleeding
omplications in Bypass Patients
he recent paper by Berger et al. (1) brings to light an important point
hat we think affects a majority of cardiologists and cardiac surgeons
like. The use of clopidogrel is now widespread, and the American
ollege of Cardiology/American Heart Association (ACC/AHA)
uidelines (2) highlight the indications for its use. However, more
ften we anecdotally observe indiscriminate use of loading dose
lopidogrel, especially by emergency room physicians and internists,
eading to delays in emergent or urgent coronary artery bypass grafting
CABG) and/or increased bleeding complications.
The guidelines (2) list a Class 1 indication for choosing between
lopidogrel or a glycoprotein IIb/IIIa inhibitor when an early
nvasive strategy is chosen in patients with unstable angina/non–
T-segment elevation myocardial infarction. The guidelines do
ot specify the timing of its use, and herein is where the problem
ies. It is reasonable to deduce from the current published data that
3) clopidogrel could be given during catheterization after coronary
natomy is determined, especially in patients going to catheteriza-
ion within 6 h and particularly in those patients that might need
ypass. These patients might be better served with more aggressive
se of other anticoagulants and glycoprotein IIb/IIIa inhibitors
hat are easily reversible, thereby circumventing having to wait 5
ays after loading dose clopidogrel.
A large study by Mehta et al. (4) showed that almost one-third
f patients needed CABG within 5 days of clopidogrel use. These
ad increased need for red cell transfusions.
Studies are lacking on how to discriminate who might need
ABG. Sadanandan et al. (5) did show that a validated risk
coring system might be applied to discriminate patients who
ight have a higher chance of needing CABG and thus holding
lopidogrel use until coronary anatomy is defined.
The authors feel that more widespread use of risk scoring
ystems might improve patient outcomes for CABG and better
iscriminate the need for loading dose clopidogrel, especially
ecause effective and quickly reversible anticoagulant agents have
een safely used and widely studied (e.g., glycoprotein IIb/IIIa
nhibitors).
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eply
e thank Drs. Patel and Mascarenhas for their insightful com-
ents. Indeed, the management algorithm for patients with
nstable angina/non–ST-segment elevation myocardial infarction
oes provide Class I options for platelet-directed pharmacotherapy
n a background of aspirin, particularly among those in whom an
arly invasive strategy is selected according to validated risk scores
1). An ability to discriminate with a high degree of accuracy
mong patients likely to require surgical revascularization would
ndoubtedly facilitate a more targeted approach to pharmacother-
py, thereby avoiding delays, concomitant risks for recurring events
2), and perioperative hemorrhagic complications (3). Clearly the
mpact of treatment decisions is far-reaching, and might well
ecome an even greater challenge with the introduction of increas-
ngly robust platelet antagonists and their accompanying pro-
onged biological half-lives.
The preemptive identification of patients with surgical anatomy
t the time of presentation is not a simple task, with existing
odels providing modest predictive accuracy and calibration (4,5).
n addition, the ultimate decision to perform surgical over percu-
aneous revascularization is influenced by many factors—patient,
amily, physician, hospital, and healthcare system-specific consid-
rations each apply. The risk of hemorrhage is also influenced by
umerous variables not restricted to antithrombotic therapy (6).
The concomitant development and carefully designed investi-
ation of short-acting or readily reversible antithrombotic agents,
oint-of-care measurement devices that permit a clear assessment
f perioperative perturbation of hemostatic potential, and high-
hroughput platforms for advanced biomarkers to better predict
atient-specific risk of bleeding (7) will collectively enrich and
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June 30, 2009:90–2ptimize the management of patients with non–ST-segment acute
oronary syndromes who require coronary artery bypass grafting.
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spirin for the Masses
he recent article by Joshi et al. (1) stressed the need for a
onphysician workforce in cardiovascular disease (CVD) manage-
ent in low- and middle-income countries. We believe that there
s a need to go one step further, considering the exigency of the
ituation. The use of aspirin for primary prevention is well
stablished and must be added to this approach at a community
evel. The combination of nonphysician health care workers
NPHWs) equipped with aspirin can potentially be a very effective
trategy. Aspirin is a drug of common social acceptance in
eveloping countries, is often readily available over the counter,
nd is easily affordable because most payments are out of pocket.
tatins and diuretics unfortunately do not share these attributes, at
east at present.
A program should be developed to teach the NPHWs thedministration of aspirin along with lifestyle modification after the bdentification of high-risk patients. This will not be easy, and a risk
ssessment tool would need to incorporate the risk of bleeding with
spirin. Routine availability of cholesterol and glucose evaluation at
he community level will remain elusive for years to come, and
linical criteria and clinical risk prediction models will have to be
elied upon. The use of a national cholesterol average as a
ubstitute is a decent suggestion in these calculations (2). The
orld Health Organization CVD risk management package has
een successfully practiced by NPHWs (3) and can be useful in
his regard.
Compliance, however, will still be the fundamental problem.
here is evidence to suggest that although interventions result in
mproved knowledge, they do not necessarily translate into practice
4). There is anecdotal evidence to suggest that people in these
ettings do not comply with medicines for which they see no overt
enefits. This necessitates that vessels of established trust be used,
here available, to spread prevention and proven intervention
and-in-hand to the current epidemic of CVD in developing
ountries.
There are many examples of effective health care delivery by
PHWs in developing world settings, such as the success of the
ntegrated Management of Childhood Illness program on an
nternational scale and the Lady Health Visitor program for female
ealth care in Pakistan (4). The latter can also serve to address the
ender inequity of health care access more effectively because of its
arge network, penetration, and reputation.
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eply
e thank Drs. Aslam and Waheed for their comments on our
ecent paper (1). They raise an important issue regarding the role
f nonphysician health care workers in the identification of
ndividuals at high risk of cardiovascular disease, such as those with
history of myocardial infarction or ischemic stroke, and their
anagement in the community with low-cost drugs such as
spirin. We agree that nonphysician health care workers
NPHWs) should be able to prescribe aspirin for secondary
revention, but we also believe that they should be able to prescribe
ther low-cost, low-risk, high-benefit treatments both for second-
ry prevention (e.g., blood pressure- and lipid-lowering drugs) and
or cardiovascular symptom management (e.g., nitrates, beta-
lockers) (2). Low-dose combination therapy for secondary pre-
